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A B S T R A C T
Nanotechnology plays an undeniable signiﬁcant role in medical sciences, particularly in the ﬁeld of biomedicine.
Development of several diagnostic procedures in medicine has been possible through the beneﬁcial application
of nano-materials, among which electrochemical nano-biosensors can be mentioned. They can be employed to
quantify various clinical biomarkers in detection, evaluation, and follow up stages of the illnesses.
MicroRNAs, a group of regulatory short RNA fragments, added a new dimension to the management and
diagnosis of several diseases. Mature miRNAs are single-stranded RNA molecules approximately 22 nucleotides
in length, which regulate a vast range of biological functions from cellular proliferation and death to cancer
development and progression. Recently, diagnostic value of miRNAs in various diseases has been demonstrated.
There are many traditional methods for detection of miRNAs including northern blotting, quantitative real time
PCR (qRT-PCR), microarray technology, nanotechnology-based approaches, and molecular biology tools in-
cluding miRNA biosensors. In comparison with other techniques, electrochemical nucleic acid biosensor
methods exhibit many interesting features, and could play an important role in the future nucleic acid analysis.
This review paper provides an overview of some diﬀerent types of nanotechnology-based biosensors for de-
tection of miRNAs.
1. Introduction
Bio-nanotechnology is one of the novel developing areas of nano-
technology, which incorporates diﬀerent ﬁelds such as engineering,
physics, as well as molecular engineering into otherscience areas in-
cluding biology, chemistry, and biotechnology. For instance, bio-na-
notechnology provides us with modern tools consisting of sensors
working based on bio-techniques, nano-based medical facilities, along
with bio-photonics [1]. Every biosensor can be an analytic system
which is comprised of a component for recognizing biological issues
when straight spatial connection is established with the conduction
component to guarantee fast and exact transformation of biologic
phenomena into quantiﬁable signals [2].
Yet, detection of valuable Nano-materials has brought about more
possibilities to carry out studies in the area of bio-sensing, while it is
also possible to provide considerable beneﬁts such as being more
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sensitive and speciﬁc than the previous bio-diagnosis [3].
Since, carbon nano-materials possess extraordinary electrical,
thermal, chemical, as well as mechanical characteristics, researchers
have been largely interested in them. Consequently, they have been
applied in various ﬁelds including composites, energy saving and con-
verting, sensors, administration of medicine, ﬁeld emission systems,
and electronic elements at nano-scale [4,5]. Furthermore, synthesis
customization is possible through connected practical elements, while
their assembly in the form of 3D arrays would help the scholars devise
catalysts with more surface area along with materials possessing high
levels of photo-chemical as well as electrochemical functions. They are
broadly applied in designing catalysts in hydrogenation, biosensors,
and fuel cells due to their extraordinary features [4].
MicroRNAs (miRNAs) are a group of small noncoding RNAs that
play an important regulatory role in gene expression at posttranscrip-
tional levels by inhibiting translation or aﬀect on RNAs degradation
[6–8]. This macromolecules are potential biomarker candidates for
diagnosis and prognosis of diﬀerent diseases [9]. However, highly
sensitive and selective methods for miRNA detection is still a challenge
because of their unique characteristics such as low abundance, small
size and high sequence homology among the family members [10–12].
Currently, the common conventional assays for miRNA detection
include northern blotting, microarray analysis and RT-PCR [13,14].
The disadvantages of these methods are complicated handling, high
costs and unstable results [15]. However, determination of miRNAs
clearly requires the development of highly sensitive techniques in order
to assess very low levels of sample in the bloodstream, and also needs to
be very selective and comply with minimum sampling volume re-
quirement, cost-eﬀectiveness, and multiplexing capabilities of a diag-
nostic test [12,16].
In recent years, various electrochemical biosensors have been
developed for the sensitive detection of miRNAs [12,17]. Electro-
chemical genosensors hold great promise to serve as devices appro-
priate for point-of-care diagnostic and multiplex platforms for fast,
simple and low-cost nucleic acids analysis as well [18]. Thus, diﬀerent
strategies have been proposed to obtain a favorable miRNA biosensor.
According to some reports, application of various enzymes which en-
gage in the oxidation-reduction reactions can be beneﬁcial in electro-
chemical miRNA biosensors, in which generation of the ﬁnal electro-
chemical signal is done by the enzymes [19,20]. It should be noted that,
these biosensors which work based on enzymes require completely
ideal circumstances to maintain the stability as well as the activity of
the enzymes when biosensor fabrication and electrochemical evalua-
tion have been done [21].
Applying conductive polymers to modify electrodes is another novel
idea, according to which the polymers and their derived forms, sig-
niﬁcantly accelerate the transmission of the electrons on the electrode.
Accordingly, this results in promotion of electrochemical function of
the electrode, while signaling identiﬁcation is also ampliﬁed [22]. In
addition, the current involvement of nano-materials in bio-sensing has
been accompanied by novel horizons toward miniaturization of the
electrochemical bio-sensors along with improving their analytic po-
tential [23]. The signiﬁcant inﬂuence of nanotechnology on the pro-
vision of electrochemical miRNA bio-sensing is considered in the fol-
lowing section.
In this review, we described miR-141, miR-155, miR-21, and Let-7
functions in human diseases especially in cancers. Afterward, we illu-
strated some sensitive and speciﬁc electrochemical biosensors for these
miRNAs.
Fig. 1. Biogenesis of microRNAs. miRNA genes
are transcribed in the nucleus and processed by
DGCR8/Pasha and the RNAse III family enzyme,
Drosha. Next, the pre-miRNA is then transported
into the cytoplasm where it is processed by Dicer
to generate a ~22 nt miRNA:miRNA* duplex.
After unwinding, the miRNA forms part of the
RISC assembly and causes translational repression
or mRNA degradation.
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2. MicroRNA: insights into its biogenesis
MicroRNAs (miRNAs) are 18–27 nucleotide-long and are categor-
ized as non-coding RNAs. ncRNAs are RNA molecules that are not
translated into a protein [24]. Recent evidence suggests that the ma-
jority of the human genomes are transcribed into ncRNAs while the
number of them is unknown. As the wide proportion of ncRNAs,
miRNAs are important parts of “dark matter” in the human genome.
Most of miRNAs are located in introns and/or exons, and also ap-
proximately 30% of miRNA genes are found in intergenic regions or in
the anti-sense orientation of genes and contain their own promoter and
regulatory units [25].
miRNA genes are transcribed by RNA polymerase II (pol II) or RNA
polymerase III (pol III) [26]. miRNA biogenesis consists of three major
steps, the ﬁrst step ocurres in the nucleus, an ~80 nt primary or pri-
miRNA is transcribed from the genome and is cleaved by a nuclear
RNase III enzyme termed Drosha [27]. That results in the formation of a
60 to 70 nucleotide stem-loop intermediate termed a pre-miRNA which
actively transported to the cytoplasm by Ran-GTP and Exportin-5 [28].
In the cytoplasm, pre-miRNA is processed by RNase III endonuclease
Dicer complex, to 20-22 nt double-stranded fragment which is in-
corporated into RNA-induced silencing complex (RISC) (Fig. 1) [29,30].
The 5′ region of miRNAs binds to the 3′ untranslated region (3’ UTR)
on target messenger RNA (mRNA) transcripts and often, they result in
translational repression or mRNA degradation [31,32]. The expression
patterns of miRNAs vary from ubiquitous up to tissue or cell-speciﬁc
and their function depends on the cell contents and target availability
within a cell [33].
3. The role of miRNAs in pathological conditions
Numerous studies have reported that certain miRNAs got highly
changed during development and also disease, such as some types of
cancers, heart diseases, diabetes, nervous system, kidney and liver
diseases etc. [34–37]. Therefore, microRNAs which are deregulated
during disease may be one of the particular research interests. its no-
teworthy that miRNA expression is a dynamical process and measure-
ment of Cell-free nucleic acid has potential to be a cost-eﬀective and
non-invasive tool for disease screening and prognosis assessment. Unit
now, it has been demonstrated that, some miRNAs like miRNA-141,
miRNA-155, Let-7, and miRNA-21, are either increased (up regulated)
or decreased (down regulated) in cancer cells [38–41]. It reveals their
potential as a class of highly sensitive and speciﬁc biomarkers for tumor
classiﬁcation and prognosis (Table 1). New diagnostic tools including
discovery and early detection of new biomarkers in addition of using
new drugs and therapies have improved diagnosis and therapy out-
comes.
3.1. miRNA-141
A growing body of studies have shown that tumor-derived miRNA-
141 deregulation in human plasma could serve as important biomarkers
for the blood-based detection of human cancers, including prostate
[42,43], colon [44] and ovarian cancers [45].
A study by de Souza et al. [42] investigated the functional role of
miRNA-141 in modulating tumorigenesis in prostate cancer. They
analyzed miRNA-141 expression in plasma samples collected from 102
untreated prostate cancer patients and of 50 healthy controls. Early
results showed that expression of the miRNA-141 was signiﬁcantly up
regulated in the metastatic patient's plasma specimens. Also, another
study of patients with prostate cancer, reported that miRNA-141 levels
in plasma can be used to screen metastatic prostate cancer with high
sensitivity [43].
Moreover, Cheng et al. reported that in 102 patients with stage IV
disease, elevated plasma miR-141 levels were also associated with
distant metastasis and poor prognosis [44]. Their data indicated that
miRNA-141 could readily discriminate distant metastasis cases from
normal controls and patients with other stages.
In addition, analysis of miRNA arrays demonstrated that miRNA-
141 was overexpressed in the endometrioid histotype compared to
normal tissue [45]. According literatures, this miRNA is an onco-sup-
pressor of BAP1 (as a BRCA1-associated protein) [46].
Furthermore, Bing Zhou et al. [47] indicated that miRNA-141 plays
an essential role during myocardial ﬁbrosis in the diabetic mice. They
found that circRNA_010567 is markedly up-regulated in diabetic mice
myocardium; sponge miRNA-141 and miRNA-141 directly target TGF-
β1, caused suppressing ﬁbrosis-associated protein resection.
Multiple studies have identiﬁed that miRNA-155 plays a signiﬁcant
role in various human cancers, including breast, lung, colon, pancreatic
and thyroid tumors [48–52].
3.2. miRNA-155
Cheng Fang and colleagues revealed that serum miRNA-155 ap-
peared to be potentially useful tools as a novel noninvasive biomarker
for diagnosis of diﬀuse large B cell lymphoma (DLBCL). Data showed
that miRNA-155 was signiﬁcantly elevated in DLBCL serum samples
compared with normal controls [53]. In addition, Costinea et al. re-
ported that miRNA-155 induces B-cell malignancies by targeting Ship
and C/EBPβ, which are two important inhibitors of the IL-6 signaling
pathway, in a transgenic mouse model [54].
Furthermore, Mattiske et al. reviewed the role of miRNA-155 in
breast cancer progression [55]. They suggested new avenues of research
for this oncogenic miRNA. Yang et al. had also the same results [56].
They performed a meta-analysis of two speciﬁc miRNAs (miRNA-155
and miRNA-21) as important prognostic classiﬁers for non-small cell
lung cancer (NSCLC). Gao et al. also introduced miRNA-155 as a di-
agnostic marker for the early detection of lung adenocarcinoma. They
demonstrated that expression of miRNA-155 was signiﬁcantly higher in
serum of lung adenocarcinoma patients than that in normal controls
[57].
Another study showed the relative expressions of miRNA-155 in
Table 1
Circulating miRNAs as diagnostic markers for diﬀerent cancer.
miRNAs alteration Type of tissue Diseases Refs.
1 MiR-141 Up Plasma Prostate cancer [43]
2 MiR-21, MiR-141 Up Plasma Ovarian cancer [123]
3 MiR-155 UP Serum Breast cancer [124]
4 MiR-155, MiR-21 Up Plasma Lung cancer [125]
5 MiR-155, MiR-21 Up Plasma Pancreatic cancer [126]
6 MiR-155, MiR-21 Up Serum DLBCL(diﬀuse large B‐cell lymphoma) [127]
7 MiR-155 Down Serum Ovarian cancer [128]
8 MiR-21 Up Serum Ovarian cancer [128]
9 let-7a Down Serum Gastric Cancer [129]
10 let-7a Down Serum Breast cancer [130]
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esophageal tissue signiﬁcantly associated with increased risk for eso-
phageal cancer [58]. Zhong-chuan et al. also performed independent
validation experiments using a large cohort of 146 patients with col-
orectal cancer (CRC) and 60 control subjects. They revealed that the
detection of miRNA-155 levels in the serum might serve as a useful
tumor biomarker in the assessment of prognosis and diagnosis of col-
orectal cancer [59].
3.3. miRNA-21
Many articles have published promising results for miRNA-21. This
miRNA not only to be used in early diagnosis and drug development in
cancer biology but also in cardiovascular disease [60–63]. In addition,
Iorio et al. showed that miRNA-21 is one of the most consistently up-
regulated miRNAs in breast cancer. Indeed, miRNA-21 is progressively
up regulated with increasing tumor stages and from normal breast to
cancer [50].
Moreover, Nam et al. demonstrated that miRNA-21 was the most
frequently up regulated miRNA in the serous ovarian carcinoma biop-
sies compared to normal control ovarian tissue. They suggested re-
levance of miRNA-21 to ovarian cancer and it may be a universal ﬂuid
biomarker for cancers [64]. In another study, northern blot results re-
vealed that the expression of miRNA-21 was signiﬁcantly increased in
21 out of 29 tumor samples [65].
Signiﬁcant up-regulation of miRNA-21 was also observed in CRC
samples that explain why high tumor-speciﬁc miRNA-21 expression
levels positively is correlated with the cancer stage and development of
distant metastases [66,67].
In another study, analysis of miRNA expression proﬁling in hepa-
tocellular carcinoma (HCC) tumor and normal liver tissues showed a
highly increased miRNA-21 expression in tumor compared to the
normal samples [68].
Moreover, miRNA-21 appears to be strongly deregulated in cardi-
ovascular disease. Tatsuguchi et al. showed that miR-21 expression is
induced during hypertrophy and, most importantly, their data suggest
miR-21 as a negative regulator in cardiac hypertrophy [62].
3.4. Let-7 family
Let-7 family has multiple isoforms and composed of nine mature
miRNAs in human body (Table 2). These isoforms encoded by 13 dis-
tinct genomic loci, some of which are clustered together [69]. Let-7 has
also been implicated in various diseases, most notably cancer [70]. In
higher organisms, reduced expression of multiple let-7 members has
been found to be associated with cancers while the levels of let-7 rise
during embryogenesis [71,72].
In many cancers, activation of non-coding genes, LIN28A and
LIN28B, two highly related RNA binding proteins (RBPs) and proto-
oncogenes, are responsible for the global post-transcriptional down
regulation of the let-7 miRNA family [73]. For example, miRNA-203
and miRNA-146a enhance let-7 biogenesis by targeting LIN28B in order
to suppress tumor growth in lung and breast cancer, respectively
[74,75].
In addition ofcancer, Let-7 family appears to be strongly deregu-
lated in cardiovascular biology and diseases. Brennan et al. reported
that let-7 levels are decreased in diabetic human carotid plaques and
suggested the restoration of let-7 expression could provide a new target
for an anti-inﬂammatory approach in diabetes-associated athero-
sclerosis [76]. Also, Faccini's study introduced let-7c, miRNA-145 and
miRNA-155 as diagnostic biomarkers in coronary artery disease [77].
4. Electrochemical-based biosensors
According to IUPAC, a biosensor is an integrated receptor trans-
ducer device, which can provide selective quantitative or semi-quanti-
tative analysis of an analyte using bio-recognition elements [78]. A
biosensor gives us rapid, real-time, precise and authentic information
about the interrogation analyte, and can detect pathogenic and phy-
siological relevant molecules with desirable sensitivity and speciﬁcity
[79,80]. This analytical device converts a biological response into a
detectable electrical signal, and functions by a biological sensing (bio-
recognition) element with a detector system using a transducer (Fig. 2)
[81]. The biosensors are mainly consist of three sections: (i) Bio-re-
cognition element can be a biological component including enzyme,
antibody, DNA, aptamer, or even a whole cell, etc.,(ii) Transducer that
is detector element and functions in a physicochemical; optical, calor-
imetrical, piezoelectrical, electrochemical approaches and etc. The
signal results from analyte and bio-recognition element interactions
will convert by transducer in order to display signals to understandable
manner, (iii) signal processing system is the associated electronic sec-
tion, which comprises of signal ampliﬁer, processor and a display unit
[82].
Hence, a new era of advancement in technology and science has
emerged by development of biosensors. Thus, due to validated results,
biosensor has been widely applied in diﬀerent scientiﬁc issues. In
medicine, they can be utilized for accurate and reliable detection of
tumors, toxins, pathogens and physiological molecules, oﬀer a powerful
opportunity in the early diagnosis and treatment of disease [83]. In this
ﬁeld, several type of biosensors based on calorimetry, piezoelectricity,
optic and as well as electrochemistry have been develop [82,84].
5. Electrochemical-based biosensors and nanotechnology
Integrating the recognition and electronic components had been the
center of emphasis through the beneﬁcial features including convenient
handling, economic feasibility, sensitivity, portability, and easy con-
struction in order to produce electrochemical sensors as well as bio-
sensors. A variety of electrochemical tools consisting of amperometrics,
sensors for electrochemical impedance, along with electrochemical lu-
minescence and photo-electrochemical sensors make a broad range of
usages regarding identiﬁcation of chemical as well as biological targets
[85].
Given the considerable accomplishments in nanotechnology and the
related sciences, augmentation of electrochemical signals based on
nano-materials has the capability to improve sensitive as well as se-
lective electrochemical and bio-sensors. Initially, the material of elec-
trodes plays an obviously essential role for establishment of highly ef-
ﬁcient electrochemical sensing systems which are able to recognize the
target molecules following diﬀerent analytic procedures [86].
Moreover, besides the material of the electrodes, these practical
nano-materials can provide synergetic eﬀects of the catalytic functions,
conduction, and bio-adaptability. This synergism enhances signal con-
duction, while it also reinforces bio-realization of the incidents through
the special signal tags which result in high sensitivity in bio-sensors.
Comprehensive studies regarding the provision of practical materials
for electrodes, along with a wide range of electrochemical procedures
have increasingly advanced the utilization of electrochemical systems
[85].
For instance, Walcarius et al. have referred to the current
Table 2
Sequence of the let-7 family miRNAs. The red nucleotides are the positions that
are identical among all members of the let-7 family.
1 Let-7a 5ˊUGAGGUAGUAGGUUGUAUAGUU 3ˊ
2 Let-7b 5ˊUGAGGUAGUAGGUUGUGUGGUU 3ˊ
3 Let-7c 5ˊUGAGGUAGUAGGUUGUAUGGUU 3ˊ
4 Let-7d 5ˊAGAGGUAGUAGGUUGCAUAGUU 3ˊ
5 Let-7e 5ˊUGAGGUAGGAGGUUGUAUAGUU 3ˊ
6 Let-7f 5ˊUGAGGUAGUAGAUUGUAUAGUU 3ˊ
7 Let-7g 5ˊUGAGGUAGUAGUUUGUACAGUU 3ˊ
8 Let-7i 5ˊUGAGGUAGUAGUUUGUGCUGUU 3ˊ
9 has-miR-98 5ˊUGAGGUAGUAAGUUGUAUUGUU 3ˊ
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developments in nano-objects as well as nano-engineered/structured
materials to provide logical bio-functional electrodes along with asso-
ciated bio-sensors [87]. These nano-materials are interesting due to
their capability of performing eﬃcient immobilization indices and their
internal as well as incomparable characteristics which were discussed
before. These characteristics along with the function of biomolecules
can inﬂuence the promotion of bio-electrode application. Hence, re-
garding the qualities of being sensitive and speciﬁc, taking nanoma-
terial-enabled paper-based biosensors such as lateral-ﬂow test-strips
and paper microﬂuidic systems into account [88].
6. Electrochemical-based biosensors in detection of miRNAs
Electrochemical biosensors hold great promises to serve as devices
that are suitable for point-of-care diagnostics and multiplex platforms
for impressive sensitive, simple and aﬀordable nucleic acid and miRNA
detection [89]. In a typical electrochemical miRNA biosensor, the
transduction element is a solid electrode, (i.e. most often gold or gra-
phite), is a selective short single-strand single nucleotide probe, which
immobilizes on electrodes. DNA probe and the target miRNA inﬂuence
the electrode or interfacial performance. Often, an electrochemically
active reporter species transduces changes in electrode properties
caused by miRNA hybridization to signal. Horse radish peroxidase
(HRP), hydrogen peroxide (H2O2), ferrocyanide (i.e., [Fe(CN)6] −3, [Fe
(CN)6] −4) glucose oxidase, alkaline phosphatase, methylene blue and
hydroquinone are some examples of electrochemically active reporters
used in miRNA detection biosensors [90–93]. Furthermore, ampero-
metric [92,94], resistive [95], potentiometric [94,96] as well as im-
pedance-based [94,97] approaches have been used to transduction.
Unique characteristics of miRNAs such as small size, extremely low
abundance in total RNA samples, and high sequence homology among
family members have made their quantitative analysis to a great chal-
lenge. In recent years, however, convenient and sensitive approaches
including rolling circle ampliﬁcation (RCA) [98], sequencing [99],
surface enhanced Raman spectroscopy (SERS) [100], bioluminescence
[101], surface plasmon resonance (SPR) spectroscopy [102], ﬂuores-
cence [103], as well as electrochemistry [104] have been developed.
Despite these approaches, given that advances of electrochemistry,
there is an impressive interesting in electrochemical methods due to
simplicity, sensitivity and low cost [19].
Generally, employing nano-materials in the layout and provision of
biosensors will reduce the size of the system and bring about additional
beneﬁcial features for eﬃcient advancements in precision and replic-
ability of the results. These features are considered important for nano-
materials, because they usually indicate new and various optic, electric,
electrochemical, as well as magnetic traits (in a size range of 1–100 nm)
in comparison with bulk forms [105]. A considerable proportion of the
surface to the volume as well as a size range like biomolecules would
account for the eﬀective reactions between nano-materials and bio-
markers without subsequent destructions [106]. Then, electrochemical
biosensors have been fabricated to determine miRNA using a broad
scope of nano-particles, rods, wires, clusters, composites, and so on. All
of them would primarily engage in amplifying electrochemical sig-
naling, bio-separating, and being a platform to immobilize biomole-
cules [23]. All of electrochemistry based miRNA detection methods,
which introduce in this literature, rely on hybridization (Table 3).
6.1. miR-141
Tran et al. reported an electrochemical immunosensor for detection
of miR-141 in which gold electrodes modiﬁed with reduced graphene
oxide (GO) and carbon nanotubes (CNT) has been applied. Amino
modiﬁed oligonucleotide capture probe was immobilized on electrodes
and complementary miRNAs added. Following hybridization, an anti-
body directed to the RNA. Then, DNA hybrids bound selectively to the
hybrids. After that, secondary antibody conjugated to horseradish
peroxidase (HRP). They used hydroquinone chromophore which is well
known to be oxidized into benzoquinone by HRP/H2O2 catalytic
system [90]. Detection limit of this method was down to 10 fM. Sche-
matic conﬁguration of this biosensor is illustrated in Fig. 3.
In another research, a label-free miR-141 sensor based on a network
of CNT and electro-active polymer was described. This one is a probe of
miR-141 that bound to Poly (JUG-co-JUGA)/o-multiwall carbon na-
notube (MWCNT)-modiﬁed electrodes (Fig. 4). Due to quinone group
embedded in polymer backbone, polymer ﬁlm presented very well
electro-active property in neutral aqueous medium. Addition of target
miR-141 increased current because of enhancement of the polymer
electro-activity, but non-complementary miRNAs could not cause any
signiﬁcant current changes [107].
Fig. 2. Schematic diagram of a biosensor. A biosensor consists of a bio-recognition element, for the speciﬁc detection of the analyte in contact to a transducer for
converting the signal into an electrically manageable format and a signal processing unit.
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6.2. miR-155
Azimizade et al. presented an oligo-hybridization-based electro-
chemical biosensor for plasma miR-155 detection [108]. This biosensor
uses gold nanorods (GNRs) decorated on GO sheets on the glassy carbon
electrode (GCE). After that, thiolated probe was immobilized on the
gold nanorods (GNRs). Following hybridization of probe and miR-155,
Oracet blue (OB) intercalated into the hybrid and reduction signals
were measured by diﬀerential pulse voltammetry (DPV) method
(Fig. 5). A linear relationship was found with the concentration of miR-
155 ranging from 2.0 fM to 8.0pM. This nano-biosensor had a great
speciﬁcity, and could discriminate sharply between complementary
target miRNAs, three-base mismatch, and non-complementary miRNAs.
Furthermore, sensitivity and selectivity of biosensor was evaluated in
plasma samples and demonstrated high functionality for direct detec-
tion of miR-155 in plasma without any sample preparation, extraction
and ampliﬁcation.
Hu et al. also developed an electrochemical biosensor for quanti-
tative detection of miR-155 [20]. Thiol-tethered oligonucleotide probes
(capture DNA) assembled on the gold electrode and then complemented
with target miRNA and aminated indicator probe (NH2-DNA). After
construction of the double strand structure, carboxyl groups of gra-
phene quantum dots (GQDs) bound to NH2-DNA and then HRP im-
mobilized on GQDs, noncovalently. HRP modiﬁed biosensor eﬀectively
catalyzed H2O2 mediated oxidation of 3, 3',5,5′-tetramethylbenzidine
(TMB) and caused a change from colorless to blue in solution as well as
an increment in electrochemical current signal (Fig. 6). This high per-
formance presented biosensor could detect 1 fM to 100 pM of miR-155
with a detection limit of 0.14 fM.
6.3. miR-21
Kilic et al. reported a novel electrochemical biosensor for detection
of miR-21 in breast cancer cell lines based on enzyme ampliﬁed method
[93]. The pencil graphite electrode (PGE) was modiﬁed by capture
probes and/or cell lysates. N-(dimethylamino) propyl-N′-ethylcarbo-
diimide hydrochloride (EDC) and N-hydroxysulfosuccinimide (NHS)
intermediated covalently attachment of probes and/or cell lysates on
surface of electrode. Hybridization was then accomplished with a bio-
tinylated complementary target. The oxidation signal of alpha naphtol,
alkaline phosphatase reaction product was detected in the presence of
the hybrid. Fabrication steps of the biosensor are demonstrated in
Fig. 7. For the ﬁrst time, they designed an enzyme based miRNA bio-
sensor for detection of miRNA from cell lysates without any modiﬁca-
tion. Compared to conventional guanine oxidation based method, the
proposed biosensor seems to provide more reproducible results for cell
lysates.
Cheng et al. also reported a novel, simple, sensitive, and speciﬁc
electrochemical biosensor based on a metal ion functionalized titanium
phosphate nanospheres for detection of miR-21 [109]. In this design
they used Cd+2 modiﬁed titanium phosphate (TiP-Cd+2) as signal unit
and two DNA capture probes. Incorporation of large amounts of Cd+2
ions into TiP nanosphere improved electrochemical signals more than 5
times. Ru (NH3)6+3 played an electron transfer mediator role that in-
teracts with DNA-base-pairs. Steps of this method have been illustrated
in Fig. 8. This method indicated a wide linear range from 1.0 aM to 10.0
pM and a substantial improvement in sensitivity which is 0.76 aM. The
proposed biosensor discriminated miR-21 target from homologous
miRNA, and detected the miRNA in human serum as well, rapidly.
Table 3
Electrochemical biosensor for detection of Let-7, miR-21, miR-141 and miR-155.
N Sensing platform Reporter Target miRNA LOD Linear range Ref
1 capture probe tagged with OsO2 nanoparticle hydrazine Let-7b 80 fM 0.30–200 pM [131]
2 miRNAs were ligated with Os(dmpy)2(IN)Cl+ ascorbic acid Let-7b 800 fM 1.0–300 nM [132]
3 Ru(PD)2Cl2 was tagged onto miRNA hydrazine Let-7b 0.20 pM 0.50–400 pM [133]
4 long oligonucleotide capture probes comprising miRNA and glucose oxidase
detection probe capturing segments
glucose Let-7c 4.0 fM 8.0 fM to 10 pM [134]
5 detection probe labeled with glucose oxidase glucose Let-7b 10 fM 20 fM to 10 pM [92]
6 target-guided formation of conducting polymer nanowires in nanogaps H2O2 let-7b 5.0 fM 10 fM to 20 pM [135]
7 oﬀ–on sensing platform based on LNA capture probe beacon H2O2 miR-21 6 fM 0.01–700 pM [136]
8 LNA hairpin probe-biotin and streptavidin-HRP H2O2 miR-21 0.4 pM 1–5000 pM [137]
9 Stem loop capture probe hybridized with target miRNA and detection probe hemin miR-21 3.96 pM 5–5000 pM [138]
10 detection based on hybridization of capture probe and target DNA, p19 binding
protein and protein displacement
K3[Fe(CN)6]
And [Ru(NH3)6]Cl
miR-21,miR-141 5 aM 10 aM -1 μM [139]
11 capture probe immobilized on Pd-Nps-modiﬁed electrode H2O2 miR-155 1.87 pM 5.6 pM −5.6×105
pM
[140]
12 target miRNA, cyt C and alcohol oxidase bound to hairpin capture probe H2O2 miR-155 0.35 fM 0.8 fM −1 nM [141]
13 anti-miR oligonucleotide immobilized on electrode Fe(CN)6 miR-155 5.7 aM 10 aM- 1.0 nM [142]
14 methylene blue-probes were released by target hybridization methylene blue and
hemin
miR-155 5.2 pM No data [143]
15 target miRNA hybridized with capture probe and made double strand DNA oracet blue miR-155 13.5 pM 50 pM −15 nM [144]
16 capture probe incorporated on tetrahedral DNA nanostructures H2O2 miR141,miR21 10 aM No data [145]
17 molecular beacon capture probe immobilized on electrode and tetrahedral DNA H2O2 miR141 1 fM No data [146]
18 hairpin capture probe of target miRNAs labeled with electrochemically active
agents
Methylene blue,
ferrocene
miR141,miR21 4.2 fM, 3 fM 5.0 fM to 50 pM [147]
Fig. 3. Schematic representation of ELISA-like immunosensor on electrodes modiﬁed with GO and CNT.
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Locked nucleic acid (LNA) is another form of RNA in which the
ribose ring is constrained by a methylene bind between the 2′-oxygen
and the 4′-carbon. This unique binding and conformation restrictions
increase binding aﬃnity for complementary sequences and decrease
non-speciﬁc binding and mismatches in double strand hybrids [110]. A
research described a highly sensitive biosensor for sequence speciﬁc
miRNA-21 detection without any labeling or enrichment [111]. This
biosensor was based on graphene, LNA integrated molecular beacon,
AuNPs and hourse radish peroxidase (HRP). LNA integrated reporter
DNA, biotin functionalized signal DNA were attached on AuNPs sur-
face. Beside, glassy carbon electrode (GCE) was functionalized with
graphene and dendritic gold nanostructures (DenAu). Substantially,
DenAu/graphene/GCE was obtained. Locked nucleic acid (LNA) in-
tegrated hairpin molecular beacon (MB) capture probes against miRNA-
21 were well aligned probe on functionalized electrode. After hy-
bridization of target miRNA-21, the stem loop structure of MB probe
was unfold and 3′-end was far away from electrode surface to hybridize
with LNA integrated DNA. So, the biotin functionalized signal DNA
loaded on AuNPs could bind with target miRNA-probe hybrids. After
that, Streptavidin-HRP interacted with biotinylated signal DNA to cat-
alyze the chemical oxidation of hydroquinone by H2O2 to form ben-
zoquinone. The electrochemical reduction of benzoquinone on am-
perometric signal was monitored the miRNA hybridization (Fig. 9). Due
to speciﬁc conﬁrmation of probe and tri-ampliﬁcation eﬀects of DenAu/
graphene/GCE, multi-functionalized Au-NPs and HRP, the biosensor
was selective and sensitive with low detection limit of 0.06pM. miRNA-
21 expression in two human cell lines (i.e. BEL-7402 as a hepato-
carcinoma cell line and L-02, anormal human hepatic cell line), has
been analyzed with this proposed biosensor, successfully.
6.4. Let-7
Ren et al. developed an ultrasensitive label-free biosensor speciﬁc
for Let-7b [112]. Thiolated DNA capture probes were immobilized on
the surface of a gold electrode, acting as target miRNA capturing in-
terface, and then were hybridized to target miRNA. Capture probes in
resulted duplexes were cleaved by duplex speciﬁc nuclease (DSN), si-
multaneously. DSN is a thermostable enzyme derived from kamchatka
crab (Paralithodes camtschaticus) that cleaves double strand (ds) DNA
and DNA in DNA-RNA hybrids with little activity toward single strand
DNA and RNA-RNA hybrids, irrespective of sequence length [113,114].
The target miRNA was released and stranded back to the sample solu-
tion and then hybridized again with remaining capture probes. Fig. 10
depicts the working principles and structure of the biosensor. So, hy-
bridization/DSN incubation formed an isothermal ampliﬁcation cycle
through which one target miRNA strand leaded to thousands of the
capture strands cleaves. Amount of miRNA was realized through dis-
tinct diﬀerence in electrochemical impedance between a control and
Fig. 4. label and reagent-free biosensor using a conducting polymer nanostructured by CNT.
Fig. 5. An electrochemical biosensor based on GO and gold nonaorod. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the
Web version of this article.)
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DSN-cleaved condition. The magnitude of the charge-transfer resistance
(Rct) of redox probes had an inverse correlation with the number of
DNA-RNA hybrids or with concentration of the target miRNA. This
method permitted the detection of target miRNA with 1.0 fM in con-
centration. Application potential of biosensors for proﬁling circulating
miRNA in blood or blood and cancerous cell total RNAs were in-
vestigated. Magnitude of Let-7a, let-7b and let-7c in Hela cells, serum
(direct analysis and extracted RNA) were measured by the proposed
biosensor. These results were consistent with those obtained by qPCR,
thus conﬁrmed the practical value of the biosensor.
Another method has been reported that is based on polymerase
extension [19]. A large amount of streptavidin loaded on Au-NPs to
make streptavidin-AuNPs (SA-AuNPs) complex (Fig. 11). This complex
and alkaline phosphatase (ALP) were responsible for signal
ampliﬁcation. Let-7a as target DNA bound to capture probe im-
mobilized on the electrode, so it could be used as a primer and triggered
a primer extension reaction. They used an isothermal DNA polymerase,
Bst DNA polymerase, which has a helicase activity and no exonuclease
activity [115,116]. During extension, polymerase incorporated bioti-
nylated nucleotides into the synthesized strand. Through the strepta-
vidin-biotin interaction, SA-AuNPs plays a role as a linker to bind
biotinylated alkaline phosphatase (biotin-ALP) to the duplex. The ALP
converted an electrochemical inactive 1-naphthyl phosphate into an
electrochemical active naphthol to generate an ampliﬁed electro-
chemical signal which exhibited a linear correlation ranging from
100 fM to 1 nM of target miRNA, with a detection limit of 99.2 fM. This
method showed high speciﬁcity to distinguish single nucleotide dif-
ferences between let7-a and other members of let family.
Fig. 6. An electrochemical miRNA biosensor based on GQD.
Fig. 7. Schematic representation of DNA-biosensor for detection of miRNA.
Z. Shabaninejad, et al. Analytical Biochemistry 581 (2019) 113349
8
7. Limitations of electrochemical miRNA nano-based biosensor for
translating to clinical settings
According to the current research, nanotechnology has a consider-
able role in advancement of diﬀerent dimensions of electrochemical
miRNA biosensing. Applying various sorts of nano-materials in
electrochemical systems is accompanied with several signiﬁcant ana-
lytic characteristics that are actually interesting to note in miRNA di-
agnostic sensitivity [117–119]. Nevertheless, some undeniable pro-
blems exist regarding the provision of these biosensors to be applied in
point of care (POC). For instance, making these systems portable is a
major challenge which needs to be dealt with. Moreover, employment
Fig. 8. Electron transfer electrochemical biosensor based on metal ion functionalized Titanium phosphate nanospheres.
Fig. 9. Electrochemical determination of miRNA based on LNA molecular beacon, dendritic AuNPs immobilized on graphen.
Fig. 10. A sensitive and selective electrochemical biosensor using DSN ampliﬁcation.
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of nano-materials has brought about several issues associated with se-
curity, adaptability, and environmental friendly traits [120]. Moreover,
provision of ideal nano-materials at the large scale in order to be uti-
lized in analytic areas would not have favorable economic outcomes or
the potential to decrease the costs of screening or diagnostic processes
[120].
Eventually, stability in the features of sensitivity and speciﬁcity are
the required criteria for many nano-biosensors which have not been
addressed yet, although stable storing potential for a long time can be
considered as one of the basic characteristics of POC systems [23].
Thus, these novel systems are still in their initial phases of appli-
cation, even though these days numerous studies have been carried out
on the devise of electrochemical transducers at nano-scale with an aim
to integrate the necessary components into a practical tool [121].
Regardless these issues, increasing development of electrochemical
nano-platforms along with the endeavors dedicated to the study and
progress of miRNA diagnostic process may meet the future expecta-
tions. As a result, acquiring a quick and cheap small tool for POC ex-
amination would be important from clinical point of view and may be
introduced in near future.
8. Conclusion
Due to the biological function of miRNAs in cancer prevention, they
were extensively used for cancer diagnosis, prognosis and treatment
over the past decade. Numerous miRNAs have diﬀerent expression
patterns and can be up-regulated or down-regulated in tumor tissues.
According to the current view, it is predicted that miRNAs can regulate
40–50% of mammalian mRNAs in translational level that reveal their
great impacts in biological processes. Therefore, there is an immediate
need to develop reliable and ultrasensitive testing platforms/tools for
miRNAs detection and quantiﬁcation as well. Today, miRNAs expres-
sion is measured by methods such as northern blot, RT-PCR, micro-
arrays, and miRNA-seq. Owing to the inherent advantages of electro-
chemical transduction methods including excellent compatibility with
advanced semiconductor technology, ease of miniaturization and low
cost, electrochemical detection of nucleic acids has the potential to be
served in high performance device at low cost with simple miniaturized
readout, and thus are reason from the challenges related to other de-
tection systems [122].
On the whole, enanobiosensors are currently developing which have
led to a novel category of inexpensive, strong, dependable, convenient,
and very sensitive diagnostic tools through connecting the beneﬁts of
electrochemical biosensing and nanotechnology. These unraveled
characteristics have provided more sensitivity, precision, and less lim-
itations in diagnosis. Therefore, elevated sensitivity would rely on more
eﬃcient sensors, while the nano-dimensions could be compared with
the size of target biomolecules, the highly large proportion of the sur-
face to volume which makes interactions much more convenient, along
with dependency on higher capture eﬃcacy of the sensors.
At the end, this review focused on the recent advances in electro-
chemical miRNA sensors. These methods may have an impact on pa-
thogens detection, genetic mutations and pharmacogenomics targets
and industrial sectors attention in near future.
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